T. André

发表

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

T. Hickish, C. Boni, J. Tabernero, 2004, The New England journal of medicine.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

A. Lièvre, P. Laurent-Puig, M. Ychou, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

R. Greil, R. Labianca, L. Collette, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

P. Laurent-Puig, E. Becht, C. Lepage, 2018, Journal of the National Cancer Institute.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms

E. Raymond, S. Faivre, C. Lombard-Bohas, 2018, Neuroendocrinology.

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

G. Curigliano, M. Fakih, M. Overman, 2022, Journal for ImmunoTherapy of Cancer.

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency

A. Duval, M. Svrcek, T. André, 2021, Cancers.

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

C. Tournigand, E. Raymond, A. Gramont, 1997, European journal of cancer.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

R. Labianca, M. Ducreux, J. Taïeb, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

David Goldstein, Florence Huguet, Franck Bonnetain, 2016, JAMA.

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Sabine Tejpar, Bruno Landi, Simona Rossi, 2014, Clinical Cancer Research.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, The Lancet. Oncology.

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.

R. Labianca, D. Kerr, D. Sargent, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

L. Quéro, T. Conroy, C. Borg, 2019, Clinical colorectal cancer.

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

A. Duval, F. Bibeau, D. Vernerey, 2017, European journal of cancer.

Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

J. Desai, H. Lenz, S. Kopetz, 2016 .

The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown

M. Ychou, E. Assenat, D. Smith, 2021, medRxiv.

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.

W. Scheithauer, F. Bonnetain, A. de Gramont, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An EGFR Pathway-Oriented Pharmacogenetic Study in MetastaticColorectal Cancer Patients Receiving Panitumumab and Irinotecan

C. Tournigand, P. Laurent-Puig, H. Blons, 2016 .

Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review

C. Tournigand, F. Bonnetain, A. de Gramont, 2015, Therapeutic advances in medical oncology.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Medical treatment and management of advanced unresectable colorectal cancer

C. Tournigand, A. Larsen, A. Gramont, 2009 .

[NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]

F. Penault-Llorca, M. Svrcek, T. André, 2020, Bulletin du cancer.

Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer

I. Sobhani, D. Le Guludec, J. Talbot, 2008, British Journal of Cancer.

Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.

B. Nordlinger, P. Rougier, J. Vaillant, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

EGFR in colorectal cancer: more than a simple receptor.

C. Létoublon, G. Milano, P. Lasser, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.

C. Tournigand, T. Hickish, C. Boni, 2010 .

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

G. Milano, L. Mineur, M. Etienne-Grimaldi, 2010, British journal of clinical pharmacology.

Update on targeted agents for adjuvant treatment of colon cancer in 2006.

C. Tournigand, A. Larsen, A. de Gramont, 2007, Gastrointestinal cancer research : GCR.

First-line therapy for advanced colorectal cancer

C. Tournigand, A. Gramont, T. André, 2005, Current oncology reports.

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial

A. Luciani, C. Tournigand, I. Sobhani, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

P. Validire, F. Bonnetain, P. Hammel, 2015, BMC Cancer.

Adjuvant therapy for stage II and III colorectal cancer.

C. Tournigand, A. Larsen, A. de Gramont, 2007, Seminars in oncology.

Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer

A. de Gramont, T. André, C. Louvet, 2003, American journal of clinical oncology.

Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).

P. Ruszniewski, P. Hammel, F. Selle, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.

M. Buyse, O. Bouché, P. Piedbois, 2001, Seminars in oncology.

A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).

C. Tournigand, A. de Gramont, T. André, 1998, European journal of cancer.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

N. Wolmark, R. Goldberg, J. Marshall, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.

C. Tournigand, J. Taieb, C. Neuzillet, 2020, Clinical colorectal cancer.

Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms.

M. Hebbar, A. de Gramont, J. Fléjou, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prognostic value and characteristics of N1c colorectal cancer

J. Lefèvre, E. Tiret, J. Fléjou, 2018, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.

F. Retornaz, J. Seitz, T. André, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.

R. Goldberg, Po-Huang Lee, A. Ohtsu, 2012, Clinical colorectal cancer.

Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies

R. Goldberg, Po-Huang Lee, A. Ohtsu, 2012, Cancer medicine.

Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies.

C. Tournigand, R. Goldberg, M. Rothenberg, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeted agents for adjuvant therapy of colon cancer.

C. Tournigand, A. Larsen, A. de Gramont, 2006, Seminars in oncology.

Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.

C. Tournigand, A. de Gramont, T. André, 2005, European journal of cancer.

Platinum-sensitivity in metastatic colorectal cancer: towards a definition.

C. Tournigand, F. Bonnetain, A. Larsen, 2013, European journal of cancer.

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer

R. Guimbaud, J. Taieb, A. Hollebecque, 2022, Cancers.

L’année 2015 à travers le regard du comité de rédaction du Bulletin du cancer

N. Magné, J. Blay, J. Thariat, 2016 .

Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study

S. Msika, M. Pocard, J. Sabate, 2016, Annals of Surgical Oncology.

Impact of Preoperative and Postoperative FOLFOX Chemotherapies in Patients with Resectable Colorectal Liver Metastasis

P. Balladur, A. Gramont, F. Paye, 2014, Journal of Gastrointestinal Cancer.

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer

C. Borg, F. Ghiringhelli, Stefano Kim, 2018, World journal of clinical oncology.

Current status of adjuvant therapy for colon cancer.

C. Tournigand, A. Barrier, P. Blanchard, 2007, Gastrointestinal cancer research : GCR.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

C. Tournigand, A. Figer, F. Bidard, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

A. de Gramont, B. Landi, T. André, 2006, British Journal of Cancer.

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.

W. Scheithauer, J. Pérez-Ruixo, Y. Humblet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Primary Tumor Location on Second‐ or Later‐line Treatment Outcomes in Patients With RAS Wild‐type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies

J. Tabernero, J. Douillard, C. Rolfo, 2018, Clinical colorectal cancer.

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

M. Ychou, B. Dréno, O. Bouché, 2012, Supportive Care in Cancer.

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

T. Hickish, C. Boni, J. Tabernero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

D. Vernerey, J. Taieb, R. Coriat, 2020, International journal of cancer.

Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2).

P. Hammel, F. Selle, B. Landi, 2004, Gastroenterologie clinique et biologique.

Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.

J. Lotz, C. Bouleuc, T. André, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.

C. Tournigand, F. Bidard, M. Hebbar, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer

C. Tournigand, A. Figer, A. de Gramont, 2007, Cancer.

Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.

C. Tournigand, A. de Gramont, T. André, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.

P. Hammel, A. de Gramont, C. Bouleuc, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.

C. Tournigand, E. Raymond, A. Gramont, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

J. Tabernero, G. Prager, A. Stein, 2021, ESMO open.

[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].

T. André, B. Chibaudel, 2013, Bulletin du cancer.

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

C. Tournigand, M. Buyse, A. de Gramont, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study

Y. Humblet, A. Zubel, A. Gramont, 2005 .

Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.

J. Tabernero, Y. Humblet, P. Soulié, 2005 .

Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years

T. Hickish, C. Boni, J. Tabernero, 2005 .

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies

J. Tabernero, J. Douillard, C. Rolfo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Bimonthly high dose leucovorin and 5‐fluorouracil 48‐hour continuous infusion in patients with advanced colorectal carcinoma

C. Tournigand, E. Raymond, A. Gramont, 1997, Cancer.

5-Fluorourcil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma A phase I-II study of two consecutive regiments

A. Sézeur, J. Lotz, D. Machover, 1993 .

Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

F. Penault-Llorca, N. Radosevic-Robin, C. Borg, 2021, Molecular oncology.

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

D. Jäger, C. Atreya, E. Van Cutsem, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study.

C. Tournigand, A. Larsen, A. de Gramont, 2020, Clinical colorectal cancer.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

R. Labianca, R. Schilsky, J. Berlin, 2018, European journal of cancer.

Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.

C. Tournigand, C. Borg, T. Mazard, 2022, European journal of cancer.

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

M. Ychou, E. Van Cutsem, A. Grothey, 2018, The oncologist.

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

L. Mineur, A. Kramar, A. Adenis, 2016, BMC Cancer.

Regorafenib for metastatic colorectal cancer

E. Raymond, A. Gramont, T. André, 2013, The Lancet.

Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status

C. Tournigand, A. Escargueil, A. Larsen, 2018, Clinical Cancer Research.

Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability

A. Duval, A. Goloudina, F. Coulet, 2018, Cellular and molecular gastroenterology and hepatology.

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers

E. Raymond, S. Faivre, C. Dreyer, 2016, Acta oncologica.

Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC)

Y. Humblet, S. Patterson, M. Peeters, 2010 .

Cancer of the pancreas.

Y. Bécouarn, P. Hammel, F. Mornex, 2006, Gastroenterologie clinique et biologique.

Fong’s Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

S. Truant, M. Hebbar, D. Vernerey, 2020, Annals of Surgical Oncology.

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre

M. Ychou, P. Rougier, R. Guimbaud, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer -A pooled analysis of 254 patients included in 2 randomised trials.

C. Tournigand, P. Rougier, D. Cunningham, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer.

A. Figer, L. Mineur, A. de Gramont, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

R. Labianca, J. Meyerhardt, E. Oki, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study.

L. Mineur, A. de Gramont, A. Gramont, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer

I. Chirivella, A. Figer, F. Rivera, 2004 .

A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer.

C. Tournigand, D. Sargent, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modified (m)Folfox7/bevacizumab (B) or modified (m)Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR)

C. Tournigand, W. Scheithauer, A. Gramont, 2007 .

Phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: preliminary safety results.

F. Lordick, M. Ducreux, Y. Hotko, 2008 .

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

P. Gibbs, L. Diaz, E. Van Cutsem, 2020, The New England journal of medicine.

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

P. Laurent-Puig, O. Bouché, T. Mazard, 2021, Clinical Cancer Research.

Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study.

E. Touboul, J. Lotz, A. de Gramont, 2000, International journal of radiation oncology, biology, physics.

Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.

Tae Won Kim, L. Diaz, E. Van Cutsem, 2017 .

OP-JNCI200054 208..211

S. Kopetz, M. Overman, V. Morris, 2021 .

Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer.

S. Kopetz, M. Overman, V. Morris, 2020, Journal of the National Cancer Institute.

Immune scores in colorectal cancer: Where are we?

A. Lièvre, M. Ducreux, J. Taïeb, 2020, European journal of cancer.

Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study

M. Pocard, O. Sgarbura, E. Gayat, 2018, Annals of Surgical Oncology.

Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.

M. Svrcek, T. André, R. Cohen, 2019, Bulletin du cancer.

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

P. Gibbs, L. Diaz, C. Punt, 2022, The Lancet. Oncology.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

M. Moore, D. Goldstein, D. Vernerey, 2016, British Journal of Cancer.

Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study

J. Desai, H. Lenz, S. Kopetz, 2018 .

Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.

A. Duval, Y. Menu, M. Svrcek, 2020, European journal of cancer.

Survey on the management of skin toxicity associated with EGFR inhibitors amongst French Physicians

M. Ychou, B. Dréno, O. Bouché, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm

M. Ychou, B. Dréno, M. Richard, 2012, Supportive Care in Cancer.

Immune checkpoint inhibitors in colorectal cancer: dream and reality.

T. André, R. Cohen, 2021, The lancet. Gastroenterology & hepatology.

Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer

A. Duval, F. Coulet, J. Godet, 2021, ESMO open.

BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database.

C. Bokemeyer, E. Van Cutsem, H. Lenz, 2021, Journal of the National Cancer Institute.

Centralized multidisciplinary team assessment of metastasis resectability in patients with metastatic colorectal cancer: A fundamental necessity

T. André, 2021, The Lancet regional health. Europe.

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

E. Van Cutsem, F. Lordick, C. Punt, 2014 .

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years

T. Hickish, C. Boni, J. Tabernero, 2007 .

Management of colorectal peritoneal metastases: Expert opinion.

M. Ychou, M. Ducreux, M. Pocard, 2019, Journal of visceral surgery.

Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, C. Punt, M. Ducreux, 2014 .

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

R. Bernards, C. Atreya, J. Schellens, 2014 .

Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).

Y. Humblet, S. Patterson, M. Peeters, 2013 .

Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of the National Cancer Institute.

Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).

R. Labianca, D. Kerr, D. Sargent, 2014 .

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients

D. Arsène, C. Lepage, G. Deplanque, 2015, PloS one.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.

C. Tournigand, R. Guimbaud, O. Bouché, 2019, European journal of cancer.

LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

J. Tabernero, A. Grothey, R. Yaeger, 2020 .

Antitumour activity of pemetrexed (Pem) and irinotecan (Iri) in second-line metastatic colorectal cancer (MCRC) patients: A multicenter phase II study

M. Hebbar, E. Gamelin, A. Gramont, 2007 .

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.

P. Laurent-Puig, C. Lepage, J. Emile, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer.

F. Sinicrope, J. Bachet, T. André, 2014, Current colorectal cancer reports.

BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT

R. Greil, S. Kubicka, T. André, 2012 .

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

C. Tournigand, P. Laurent-Puig, F. Penault-Llorca, 2013 .

386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers

L. Diaz, P. Ascierto, A. Joe, 2017 .

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

C. Tournigand, A. Lièvre, G. Piessen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

497OBEVACIZUMAB-ERLOTINIB AS MAINTENANCE THERAPY IN METASTATIC COLORECTAL CANCER. FINAL RESULTS OF THE GERCOR DREAM STUDY.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer : A gercor randomized open-label phase III study.

C. Tournigand, P. Laurent-Puig, F. Bonnetain, 2014 .

Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II evaluation of an alternated FOLFOX/FOLFIRI regimen in patients with resistant metastatic colorectal cancer (CRC)

C. Tournigand, M. Hebbar, A. Gramont, 2001 .

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Addition of oxaliplatin (Eloxatine®, LOHP) to the same leucovorin (LV) and 5 fluorouracil (5FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary report

O. Bouché, A. Gramont, T. André, 1997 .

[Colon cancer: what is new in 2004?].

A. de Gramont, T. André, C. Louvet, 2004, Bulletin du cancer.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019 .

Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results

F. Lordick, M. Ducreux, Y. Hotko, 2008 .

LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)

C. Atreya, M. Ducreux, J. Schellens, 2015 .

Cetuximab and irinotecan-based chemotherapy as an active and safe treatment option for elderly patients with extensively pre-treated metastatic colorectal cancer

J. Tabernero, F. Lévi, P. Rougier, 2007 .

Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC).

C. Tournigand, F. Bonnetain, A. de Gramont, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy.

C. Tournigand, A. Larsen, T. André, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

F. Lordick, M. Ducreux, Y. Hotko, 2009 .

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

N. Wolmark, E. Van Cutsem, R. Goldberg, 2019, Journal of Clinical Oncology.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

C. Borg, B. Buecher, O. Bouché, 2018, The Lancet. Oncology.

Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.

T. André, M. Salem, R. Cohen, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

533PA large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability

J. Taieb, R. Coriat, T. André, 2017 .

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

E. Van Cutsem, R. Goldberg, D. Haller, 2020 .

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin.

D. Vernerey, J. Taieb, M. Svrcek, 2020, Journal of the National Cancer Institute.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Journal of Clinical Oncology.

Letter to the Editor from Colle et al

Y. Menu, T. André, R. Colle, 2021, Journal for ImmunoTherapy of Cancer.

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.

P. Gibbs, L. Diaz, Ping Yang, 2020, Journal of Clinical Oncology.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

M. Sawyer, E. Van Cutsem, H. Lenz, 2019, Journal of Clinical Oncology.

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

J. Desai, H. Lenz, B. Neyns, 2017 .

Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.

R. Greil, S. Kubicka, T. Mueller, 2013 .

Efficacy and Safety of Treatment with Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with BEV + CT: Age Subgroup Analysis From a Randomised Phase III Intergroup Study (ML18147)

O. Bouché, D. Arnold, T. André, 2012 .

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

S. Jaeger, C. Atreya, M. Ducreux, 2016 .

[Adenocarcinoma of the pancreas. General characteristics].

J. Gligorov, A. de Gramont, J. Balosso, 1998, Presse medicale.

[Adenocarcinoma of the pancreas. Therapeutic strategies].

E. Touboul, J. Vaillant, J. Lotz, 1998, Presse medicale.

Phase II trial of high dose adjuvant chemo-radiotherapy (55 Gy in 5 wks) after resection of pancreatic adenocarcinoma

P. Hammel, J. Balosso, T. André, 2004 .

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

L. Mineur, A. Kramar, A. Adenis, 2016, BMC Cancer.

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

P. Hammel, M. Wislez, M. Svrcek, 2016, Bulletin du cancer.

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

R. Labianca, J. Meyerhardt, M. Buyse, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

A phase II study of gemcitabine and oxaliplatin (gemox) in advanced biliary adenocarcinoma (ABA). Preliminary results

C. Tournigand, F. Selle, A. Gramont, 2001 .

High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor‐prognosis germ cell tumors and metastatic trophoblastic disease in adults

J. Lotz, C. Bouleuc, T. André, 1995, Cancer.

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

Isabelle Salmon, Kathryn Graham, John R Mackey, 2012, Gastroenterology.

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of Clinical Oncology.

[Therapeutic intensification and hematopoietic stem cell autotransplantation in the treatment of solid tumors in adults: principles, realization and application to the treatment of germ cell, trophoblastic, breast, ovarian and small-cell bronchial tumors. 1].

C. Gisselbrecht, F. Pène, J. Lotz, 1995, La Revue de medecine interne.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

A. Duval, J. Vaillant, J. Iovanna, 2017, Gastroenterology.

Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.

M. Sawyer, H. Lenz, B. Neyns, 2018 .

Performance of Next Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer with Deficient DNA Mismatch Repair.

M. Sanson, A. Duval, G. Piessen, 2021, Gastroenterology.

LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours

A. Lièvre, E. Baudin, A. Couvelard, 2019, Neuroendocrinology.

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

J. Malvehy, P. Ascierto, P. V. Van Schil, 2022, Healthcare.

Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial

C. Borg, Stefano Kim, T. André, 2022, Frontiers in Oncology.

[Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?].

M. Ychou, D. Franco, J. Raoul, 2014, Bulletin du cancer.

PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer--A GERCOR Study.

F. Bonnetain, P. Hammel, A. Gramont, 2015 .

FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial.

T. Hickish, C. Boni, J. Tabernero, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.

D. Jäger, L. Diaz, J. Bendell, 2017 .

FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.

C. Tournigand, T. Hickish, C. Boni, 2010 .

DPD deficiency: Medicoeconomic evaluation of pretreatment screening of 5-FU toxicity.

G. Hunault, E. Gamelin, M. Boisdron-Celle, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.

P. Gibbs, Ping Yang, C. Punt, 2021 .

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

D. Berton, G. Curigliano, S. Ellard, 2021 .

E. Van Cutsem, M. Amonkar, D. Smith, 2020, Annals of Oncology.

Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.

B. Neyns, S. Kopetz, M. Overman, 2018 .

A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.

J. Tabernero, N. Amellal, A. Cervantes, 2017 .

MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).

E. Van Cutsem, J. Tabernero, A. Cercek, 2021 .

Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients

M. Buyse, O. Bouché, E. Gamelin, 2005 .

Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.

R. Labianca, D. Sargent, S. Thibodeau, 2014 .

mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study.

C. Tournigand, W. Scheithauer, A. de Gramont, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.

R. Motzer, J. Larkin, J. McQuade, 2022, JAMA oncology.

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.

J. Lotz, A. de Gramont, A. Gramont, 1999, European journal of cancer.

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

P. Laurent-Puig, M. Ychou, G. Deplanque, 2019, Annals of Oncology.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

M. Ychou, B. Dréno, P. Gourraud, 2012, The oncologist.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

M. Sawyer, E. Van Cutsem, H. Lenz, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

J. Desai, H. Lenz, S. Kopetz, 2017, The Lancet. Oncology.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

D. Sargent, M. Shah, D. Haller, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer.

C. Tournigand, A. de Gramont, A. Larsen, 2011, Seminars in oncology.

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.

P. Mohanty, T. Hickish, L. Wyrwicz, 2017, The Lancet. Oncology.

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.

C. Tournigand, B. Gayet, F. Selle, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

J. Hecht, R. Salazar, E. Van Cutsem, 2012, The Lancet. Oncology.

Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma

I. Salmon, J. Devière, J. Vaillant, 2014, Clinical Cancer Research.

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

A. Lièvre, M. Ychou, O. Bouché, 2016, Clinical colorectal cancer.

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas

L. Alexandrov, J. Zucman‐Rossi, E. Letouzé, 2017, The Journal of pathology.

Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives

A. Duval, M. Svrcek, T. André, 2017 .

Immunotherapy and patients treated for cancer with microsatellite instability.

A. Duval, J. Lefèvre, J. Fléjou, 2017, Bulletin du cancer.

Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.

A. Duval, J. Bachet, R. Lupinacci, 2019, Surgical oncology.

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group

J. Blay, M. Montemurro, O. Bouché, 2014, BMC Cancer.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

C. Tournigand, W. Scheithauer, D. Vernerey, 2015, The Lancet. Oncology.

Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer

A. Duval, V. Jonchère, F. Paye, 2021, Journal for ImmunoTherapy of Cancer.

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group

J. Blay, M. Montemurro, O. Bouché, 2014, BMC Cancer.

EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies

C. Tournigand, A. Escargueil, V. Poindessous, 2011, Clinical Cancer Research.

A comprehensive overview of promising biomarkers in stage II colorectal cancer.

J. Taieb, M. Svrcek, T. André, 2020, Cancer treatment reviews.

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

J. Millholland, C. Atreya, E. Van Cutsem, 2020, Clinical Cancer Research.

Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond

T. André, R. Cohen, R. Colle, 2019, Targeted Oncology.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

T. Hickish, R. Salazar, J. Tabernero, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).

C. Lepage, R. Guimbaud, V. Boige, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?

C. Dreyer, P. Cervera, A. Gramont, 2017, Current Treatment Options in Oncology.

Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.

W. Scheithauer, T. Hickish, J. Tabernero, 2013 .

Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.

E. Touboul, L. Mineur, J. Balosso, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

E. Touboul, R. Labianca, P. Ruszniewski, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant administration of weekly oxaliplatin, 5FU continuous infusion and radiotherapy in locally advanced pancreatic cancer (LAPC): A GERCOR phase II study.

E. Touboul, L. Mineur, J. Balosso, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tandem high‐dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma

E. Touboul, J. Lotz, C. Bouleuc, 1996, Cancer.

C. Tournigand, P. Laurent-Puig, F. Penault-Llorca, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

R. Labianca, D. Sargent, M. Buyse, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

E. Van Cutsem, Y. Humblet, S. Patterson, 2013, Clinical Cancer Research.

Therapeutic strategy in unresectable metastatic colorectal cancer

C. Tournigand, A. de Gramont, T. André, 2012, Therapeutic advances in medical oncology.

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status

A. Duval, F. Bibeau, J. Fléjou, 2019, JAMA oncology.

[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].

J. Blay, J. Thariat, J. Bay, 2011, Bulletin du cancer.

[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].

J. Blay, J. Thariat, J. Bay, 2011, Bulletin du cancer.

Differential expression of the CCK‐A and CCK‐B/gastrin receptor genes in human cancers of the esophagus, stomach and colon

N. Vaysse, T. André, C. Escrieut, 1997, International journal of cancer.

Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study

P. Laurent-Puig, F. Penault-Llorca, C. Létoublon, 2014, British Journal of Cancer.

DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer : New therapeutic opportunities ? 2

A. Duval, M. Pocard, C. Dreyer, 2019 .

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, A. Grothey, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer.

G Milano, C. Létoublon, G. Milano, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab efficacy in patients treated routinely in university hospitals.

A. Lièvre, F. Lévi, P. Rougier, 2007, Gastroenterologie clinique et biologique.

Prognostic Impact of Deficient DNA Mismatch Repair and KRAS and BRAFV600E Mutations in Patients with Lymph-Node-Positive Colon Cancer

F. Sinicrope, J. Bachet, T. André, 2014, Current Colorectal Cancer Reports.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

T. Conroy, J. Bosset, O. Bouché, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

C. Tournigand, C. Borg, T. Mazard, 2020, Journal for ImmunoTherapy of Cancer.

Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group.

J. Blay, A. Cesne, A. Italiano, 2020, AJR. American journal of roentgenology.

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

T. Mazard, Stefano Kim, M. Wagner, 2019, Cancer Imaging.

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

J. Tabernero, N. Amellal, A. Cervantes, 2019, European journal of cancer.

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

C. Tournigand, G. Deplanque, F. Bonnetain, 2019, International journal of oncology.

Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.

J. Taieb, A. Berger, C. Lagorce-Pagès, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.

M. Mareel, E. Bruyneel, J. Mester, 2002, Cancer research.

Vegf, vegf‐B, vegf‐C and their receptors KDR, FLT‐1 and FLT‐4 during the neoplastic progression of human colonic mucosa

J. Vaillant, T. André, C. Gespach, 2000, International journal of cancer.

Para-aortic lymph node metastasis detected intraoperatively by systematic frozen section examination in pancreatic head adenocarcinoma: is resection improving the prognosis?

P. Balladur, F. Paye, M. Svrcek, 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

P. Validire, F. Bonnetain, P. Hammel, 2015, BMC Cancer.

Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma

J. Emile, P. Hammel, Y. Godfrin, 2015, Pancreas.

[Nab-paclitaxel].

T. André, S. Dumont, Daniel Lopez-Trabada Ataz, 2015, Bulletin du cancer.

Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

D. Sargent, R. Goldberg, A. Grothey, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.

C. Tournigand, F. Bonnetain, A. Larsen, 2011, The oncologist.

Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.

J. Taieb, T. André, E. Auclin, 2019, Cancer treatment reviews.

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

P. Rougier, J. Douillard, A. de Gramont, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.

M. Ducreux, O. Bouché, A. de Gramont, 2011, Anticancer research.

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

C. Borg, B. Buecher, O. Bouché, 2022, European Journal of Cancer.

Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.

J. Blay, F. Bertucci, C. Lucchesi, 2019, The Lancet. Oncology.

KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).

D. Jäger, L. Diaz, J. Bendell, 2018 .

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?

A. de Gramont, T. Poussa, P. Bono, 2014, European journal of cancer.

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study

P. Laurent-Puig, A. Sauvanet, J. Emile, 2019, British Journal of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer

A. Duval, M. Pocard, C. Dreyer, 2016, Current Oncology Reports.

E. Van Cutsem, Ping Yang, C. Punt, 2021, The Lancet. Oncology.

Tomographie par émission de positons et cancers digestifs

E. Touboul, P. Rougier, P. Ruszniewski, 2008 .

Molecular Targets for the Treatment of Metastatic Colorectal Cancer

T. André, R. Cohen, R. Colle, 2020, Cancers.

Adjuvant therapy in patients with stage II and III colon cancer under 70 years of age

A. Gramont, T. André, S. Dumont, 2013 .

The evolution of adjuvant therapy in the treatment of early-stage colon cancer.

C. Tournigand, A. de Gramont, A. Larsen, 2011, Clinical colorectal cancer.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

J. Pignon, M. Ducreux, T. Greten, 2014, The Lancet. Oncology.

[Malignant biliary obstruction, general review and clinical practice].

T. André, E. Bensoussan, C. Liguory, 2013, Bulletin du cancer.

[Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer].

J. Blay, M. Wislez, C. Massard, 2010, Bulletin du cancer.

Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study

F. Pruvot, M. Hebbar, F. Bonnetain, 2013, Journal of chemotherapy.

[Familial adenomatous polyposis, desmoid tumors and Gardner syndrome].

T. André, Y. Parc, Daniel Lopez-Trabada Ataz, 2019, Bulletin du cancer.

Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).

F. Penault-Llorca, N. Radosevic-Robin, P. Bourgoin, 2021 .

Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.

C. Tournigand, O. Hentic, A. de Gramont, 2015, Bulletin du cancer.

DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.

J. Blay, F. Bertucci, F. Petitprez, 2018 .

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

E. Van Cutsem, J. Tabernero, G. Tortora, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.

C. Tournigand, S. Oudard, P. Cottu, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy

M. Tauber, A. Mékinian, T. André, 2018, Clinical Rheumatology.

Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.

D. Ball, T. André, J. Kaye, 2015, Clinical therapeutics.

[Disseminated and circulating tumor cells in gastrointestinal oncology].

F. Bidard, J. Pierga, P. Mariani, 2012, Bulletin du cancer.

Disseminated and circulating tumor cells in gastrointestinal oncology.

M. Ducreux, F. Bidard, J. Pierga, 2012, Critical reviews in oncology/hematology.

Molecular analysis of sentinel lymph node in colon carcinomas by one-step nucleic acid amplification (OSNA) reduces time to adjuvant chemotherapy interval.

M. Pocard, C. Eveno, T. André, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

O. Bouché, A. de Gramont, T. André, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.

R. Labianca, J. Meyerhardt, V. Torri, 2020, The Lancet. Oncology.

Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.

O. Mir, M. Ducreux, F. Goldwasser, 2016, European journal of cancer.

Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer

F. Bonnetain, A. Larsen, A. Gramont, 2013, Current Colorectal Cancer Reports.

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

C. Tournigand, F. Bonnetain, P. Hammel, 2017, The lancet. Gastroenterology & hepatology.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

C. Tournigand, P. Laurent-Puig, F. Bonnetain, 2015, BMC Cancer.

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

J. Lotz, A. de Gramont, A. Gramont, 1999, European journal of cancer.

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

S. Reingold, W. Scheithauer, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR).

Y. Bécouarn, J. Emile, F. Bibeau, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial

S. Gill, J. Emile, J. Taïeb, 2019, Clinical colorectal cancer.

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

C. Tournigand, D. Sargent, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.

C. Tournigand, L. Mineur, A. Larsen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

C. Tournigand, M. Buyse, I. Chirivella, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer

E. Van Cutsem, J. Tabernero, Tae Won Kim, 2020, JAMA network open.

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

P. Gibbs, C. Punt, Tae Won Kim, 2021 .

Microsatellite Status and Adjuvant Chemotherapy in Patients with Stage II Colon Cancer

P. Laurent-Puig, A. Gramont, J. Bachet, 2010 .

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

M. Buyse, O. Bouché, A. de Gramont, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Marc Buyse, Pascal Piedbois, Thierry Andre, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stage II and Stage III Colon Cancer: Treatment Advances and Future Directions

C. Tournigand, A. Larsen, A. de Gramont, 2010, Cancer journal.

Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.

M. Buyse, M. Ychou, P. Rougier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.

D. Berton, G. Curigliano, S. Cresta, 2021 .

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

Brian Bot, Greg Yothers, Qian Shi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future

Q. Shi, T. André, R. Cohen, 2020, Cancers.

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

W. Scheithauer, P. Ross, L. Fartoux, 2008, British Journal of Cancer.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

L. Mineur, A. Kramar, A. Adenis, 2016, BMC Cancer.

Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

C. Tournigand, M. Buyse, I. Chirivella, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

C. Tournigand, M. Hebbar, A. de Gramont, 2006, Cancer investigation.

[Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].

C. Tournigand, E. Raymond, A. de Gramont, 1997, La Revue de medecine interne.

T. Hickish, C. Boni, J. Tabernero, 2009 .

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

R. Greil, S. Kubicka, E. Van Cutsem, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).

M. Buyse, A. de Gramont, T. André, 2010, Clinical colorectal cancer.

HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer

H. Blanché, C. Lepage, A. Duval, 2016, Journal of Medical Genetics.

Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.

T. Bekaii-Saab, D. Goldstein, D. Cunningham, 2020, Journal of hepatology.

[Adjuvant treatment of colon cancer MOSAIC study's main results].

C. Tournigand, A. de Gramont, T. André, 2006, Bulletin du cancer.

Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSé Program.

C. Tournigand, G. Ferretti, G. Vassal, 2015 .

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

D. Sargent, M. Buyse, C. Boni, 2006, Annals of Surgical Oncology.

Prognostic Factor Analysis in Advanced Gastric Cancer Patients Treated with Hydroxyurea, Leucovorin, 5-Fluorouracil, and Cisplatin (HLFP Regimen)

J. Vaillant, A. de Gramont, E. Gamelin, 2003, Cancer investigation.

A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification.

J. Meyerhardt, I. Nagtegaal, J. Tabernero, 2021, Cancer treatment reviews.

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Daniel J Sargent, Greg Yothers, Lindsay A Renfro, 2014, Journal of the National Cancer Institute.

MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

M. Salto‐Tellez, F. Nicolantonio, A. Bardelli, 2016 .

Abstract 1396: Validation of a MEK/MET-specific NGS panel for early phase trial interrogation

P. Maxwell, A. Bardelli, P. Laurent-Puig, 2016 .

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

R. Labianca, D. Kerr, D. Sargent, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

J. Tabernero, F. Lévi, P. Rougier, 2008, Critical reviews in oncology/hematology.

First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.

A. Falcone, N. Amellal, T. André, 2020, Future oncology.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.

J. Bosset, P. Maingon, C. Borg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).

C. Tournigand, J. Lotz, A. de Gramont, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.

L. Diaz, Tae Won Kim, R. Guimbaud, 2020 .

484PDAnalysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142

Hao Tang, S. Kopetz, M. Overman, 2017 .

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

R. Labianca, J. Meyerhardt, E. Oki, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new prognostic and predictive tool for shared decision making in stage III colon cancer.

A. Shields, P. Bruzzi, A. Grothey, 2020, European journal of cancer.

"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".

C. Lepage, J. Emile, J. Taïeb, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.

Y. Doki, B. Melichar, S. Clarke, 2017 .

The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

Y. Bécouarn, O. Bouché, F. Bonnetain, 2016 .

A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW.

H. Lenz, S. Tejpar, J. Novotny, 2020, Journal of Clinical Oncology.

Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142.

M. Overman, K. Cocks, C. Yip, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

M. Hebbar, A. de Gramont, E. Gamelin, 2010, Journal of oncology.

GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma : final results of the GERCOR /GISCAD Intergroup Phase III.

R. Labianca, M. Ducreux, A. Zaniboni, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant alpha-2b interferon and doxorubicin: results of a pilot study.

C. Bouleuc, T. André, D. Lamarque, 1994, European journal of cancer.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2020 .

Animal Models to Test Adjuvant Treatment: An Experimental Model of Colon Cancer

M. Pocard, C. Eveno, T. André, 2013, Current Colorectal Cancer Reports.

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

C. Borg, B. Buecher, O. Bouché, 2020, Therapeutic advances in medical oncology.

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.

I. Salmon, J. Vaillant, A. Sauvanet, 2013, European journal of cancer.

Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.

I. Salmon, P. Rougier, J. Vaillant, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.

D. Sargent, B. Bot, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to M. Gallén et al and R.S. Midgley et al.

C. Tournigand, A. de Gramont, T. André, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Chemotherapy of colorectal cancers with metastases].

C. Tournigand, E. Raymond, A. de Gramont, 1996, Presse medicale.

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in poor prognosis patients with metastatic colorectal cancer.

C. Tournigand, I. Chirivella, A. Figer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

N. Tomita, T. Yamanaka, N. Wolmark, 2021, Journal of the National Cancer Institute.

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

J. Lotz, A. de Gramont, A. Gramont, 2001, European journal of cancer.

FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.

C. Tournigand, M. Buyse, A. Figer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

M. Loriot, J. Thariat, O. Bouché, 2019, Bulletin du cancer.

Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study.

B. Gayet, A. Figer, A. de Gramont, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

C. Tournigand, B. Gayet, J. Taïeb, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

M. Ychou, E. Assenat, D. Botsen, 2021, JAMA network open.

[BRAF V600E-mutant colorectal cancers: Where are we?]

A. Lièvre, T. André, E. Samalin, 2020, Bulletin du Cancer.

[HER2 and gastric cancer. Recommendations for clinical practice in 2011].

F. Penault-Llorca, J. Emile, O. Bouché, 2011, Annales de pathologie.

A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer

M. Ducreux, O. Bouché, A. Gramont, 2008 .

Chimiothérapies anticancéreuses et personnes âgées : revue de la littérature Anticancer chemotherapy in the elderly: a review of the litterature

J. Lotz, I. Debrix, T. André, 2008 .

Accuracy of Predefined Hypotheses in Colon Cancer Adjuvant Phase III Trials: Observations and Recommendations

A. Larsen, A. Gramont, T. André, 2014, Current Colorectal Cancer Reports.

Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer.

D. Sargent, A. Grothey, T. André, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of Oncology.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

M. Ducreux, P. Soulié, M. Marty, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[Lynch syndrome: What is new?]

A. Duval, F. Coulet, M. Svrcek, 2018, Bulletin du cancer.

An overview of adjuvant systemic chemotherapy for colon cancer.

A. de Gramont, T. André, 2004, Clinical colorectal cancer.

Frequent intragenic rearrangements of DPYD in colorectal tumours

P. Laurent-Puig, C. Létoublon, G. Milano, 2014, The Pharmacogenomics Journal.

MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

M. Salto‐Tellez, F. Nicolantonio, A. Bardelli, 2015 .

Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.

M. Hidalgo, B. Saez, E. Raymond, 2013 .

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma

Sung-Bae Kim, C. Borg, B. Buecher, 2019, Annals of Oncology.

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

C. Tournigand, H. Sokol, A. Duval, 2020 .

Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

R. Labianca, D. Sargent, E. Van Cutsem, 2016, Journal of geriatric oncology.

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

C. Atreya, J. Schellens, J. Tabernero, 2015 .

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

L. Fornaro, S. Lonardi, F. Pietrantonio, 2023, Journal for ImmunoTherapy of Cancer.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Christophe Tournigand, Franck Bonnetain, Olivier Dupuis, 2016, Cancer medicine.

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2015 .

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2019, Journal of Clinical Oncology.

Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.

J. Desai, H. Lenz, B. Neyns, 2017 .

Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma.

G. Piessen, M. Svrcek, T. André, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[Anticancer chemotherapy in the elderly: a review of the literature].

B. Milleron, J. Gligorov, J. Lotz, 2008, Bulletin du Cancer.

Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use.

P. Laurent-Puig, B. Nordlinger, J. Vaillant, 2017 .

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study

P. Laurent-Puig, A. Sauvanet, J. Emile, 2019, British Journal of Cancer.

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.

C. Bokemeyer, E. Van Cutsem, C. Punt, 2021, Journal of the National Cancer Institute.

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.

R. Salazar, E. Van Cutsem, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

G. Lenaers, A. de Gramont, E. Gamelin, 2004, Bulletin du cancer.

Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.

C. Tournigand, E. Raymond, S. Faivre, 2005, International journal of oncology.

[Irinotecan in combination for colon cancer].

M. Ychou, M. Ducreux, D. Khayat, 1998, Bulletin du cancer.

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study.

E. Van Cutsem, T. Price, J. Seitz, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

502PDMOSAIC STUDY: ACTUALIZATION OF OVERALL SURVIVAL (OS) WITH 10 YEARS FOLLOW UP AND EVALUATION OF BRAF. BY GERCOR AND MOSAIC INVESTIGATORS.

W. Scheithauer, T. Hickish, A. Duval, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

548PIMPACT OF BASELINE COVARIATES AND PRIOR THERAPY ON THE EFFICACY OF SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer

P. Gibbs, C. Punt, Tae Won Kim, 2022, Cancer science.

A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).

C. Tournigand, R. Guimbaud, Anu Gupta, 2017 .

Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012 .

Safety analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan in resected stages II-III rectal cancers

M. Ychou, P. Rougier, J. Douillard, 2008 .

Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).

A. Luciani, C. Tournigand, I. Sobhani, 2017 .

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency

A. Duval, F. Bibeau, D. Vernerey, 2019 .

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer

E. Van Cutsem, V. Heinemann, G. Bodoky, 2023, ESMO open.

Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.

F. Moiseenko, A. Falcone, N. Amellal, 2022, The Lancet Gastroenterology and Hepatology.

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

D. Vernerey, J. Taieb, A. de Gramont, 2018, European journal of cancer.

[DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].

A. Duval, M. Pocard, A. de Gramont, 2015, Bulletin du Cancer.

Quels changements dans le Thsaurus National de Cancrologie Digestive en 2005

M. Ducreux, P. Rougier, D. Peiffert, 2006 .

[Targeting HER2 in colorectal cancer].

R. Cohen, P. Cervera, T. André, 2023, Bulletin du cancer.

Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.

M. Moore, D. Goldstein, D. Vernerey, 2015 .

Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.

L. Diaz, J. Bendell, D. Jaeger, 2017 .

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

C. Tournigand, M. Buyse, A. de Gramont, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

F. Lordick, M. Ducreux, Y. Hotko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].

T. André, B. Chibaudel, 2013, Bulletin du cancer.

Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT)

M. Ducreux, B. Asselain, T. André, 2017, Clinical colorectal cancer.

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial

M. Hebbar, F. Bonnetain, A. de Gramont, 2016, PloS one.

[DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].

A. Duval, M. Pocard, A. de Gramont, 2015, Bulletin du cancer.

[2015 through the eyes of the Bulletin of Cancer editorial board].

N. Magné, J. Blay, J. Thariat, 2016, Bulletin du cancer.

D. Goldstein, O. Bouché, F. Bonnetain, 2016, JAMA.

L. Mineur, A. Kramar, A. Adenis, 2016, BMC Cancer.

Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma

P. Hammel, L. de Mestier, J. Cros, 2021, Therapeutic advances in medical oncology.

546PTUMOUR SHRINKAGE AND RESPONSE OUTCOMES DURING SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT.

F. Lordick, C. Punt, M. Ducreux, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.

E. Van Cutsem, H. Lenz, A. Cercek, 2023, The Lancet. Oncology.

Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma

J. Vaillant, P. Cervera, T. André, 2019, Case reports in gastrointestinal medicine.

Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.

E. Van Cutsem, C. Punt, J. Tabernero, 2023, Journal of Clinical Oncology.

[Perioperative treatment for resectable esogastric adenocarcinoma].

R. Cohen, T. André, R. Cohen, 2022, Bulletin du cancer.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients

D. Arsène, C. Lepage, G. Deplanque, 2015, PloS one.

5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer.

I. Chirivella, A. Figer, F. Rivera, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

306 Optimox study: Folfox7 compared to folfox4 in metastatic colorectal cancer (CRC). Results of a randomized study

A. Figer, F. Rivera, A. Gramont, 2003 .

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

P. Hammel, M. Wislez, M. Svrcek, 2016, Bulletin du cancer.

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.

J. Tie, M. Peeters, S. Siena, 2023, Journal of Clinical Oncology.